Upadacitinib, a selective oral JAK1 inhibitor, has been approved by the U. S. Food and Drug Administration (FDA) for the treatment of moderate-to-severe atopic dermatitis (AD) (4). This evidence concerns the gene JAK1 and Alzheimer disease.